Does Blue Cross Blue Shield Cover Dayvigo (Lemborexant)?

How BCBS Plans Typically Handle Dayvigo Coverage

Blue Cross Blue Shield is not one insurer. It is a federation of 34 independent companies operating across all 50 states and the District of Columbia, each setting its own formulary and utilization management rules. A BCBS plan in Illinois may place Dayvigo on Tier 3 with a $50 copay, while a BCBS plan in Texas may list it as non-preferred brand with a $75 copay and mandatory step therapy.

The Federation Structure Matters

Because each BCBS affiliate writes its own pharmacy benefit, there is no single national formulary for Dayvigo. The Federal Employee Program (FEP), which covers roughly 5.3 million federal workers and dependents, maintains a separate formulary from state-level commercial or marketplace plans 1. If you carry a BCBS FEP card, your coverage rules differ from a coworker on a state-level BCBS PPO.

Checking Your Specific Plan

The fastest way to confirm coverage is to log into your BCBS member portal and search the formulary for "lemborexant" or "Dayvigo." You can also call the number on the back of your card and ask the pharmacy benefit team three questions: (1) Is Dayvigo on my formulary? (2) What tier? (3) Is prior authorization or step therapy required?

What "Plan-Specific" Actually Means

BCBS affiliates that list Dayvigo as "plan-specific" are signaling that employer groups within that affiliate can opt in or out of coverage. A large self-funded employer might carve Dayvigo into its plan while a small-group HMO excludes it. This is why two people with the same BCBS logo on their card can get different answers.

Formulary Tier and Cost Expectations

Dayvigo typically lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand) across BCBS commercial plans. Tier 3 copays generally range from $35 to $60 per 30-day supply, while Tier 4 copays can run $60 to $100 or require coinsurance of 25% to 50% after the deductible.

Brand vs. Generic Pricing Context

No generic version of lemborexant is available as of mid-2026. Eisai holds patent protection, keeping Dayvigo in the brand-only tier. The wholesale acquisition cost sits near $320 per month 2. Cash-pay prices through discount programs like GoodRx or RxSaver average around $85 per month, which occasionally undercuts the insured copay on a high-tier plan.

High-Deductible Plans

If you carry a BCBS high-deductible health plan (HDHP), you will pay the full negotiated rate until your deductible is met. That negotiated rate is often $150 to $250 per month, not the $320 list price. Once the deductible clears, your copay or coinsurance kicks in at the formulary tier rate.

Prior Authorization Requirements

Most BCBS affiliates require prior authorization (PA) for Dayvigo. PA means your prescriber must submit clinical documentation to BCBS demonstrating that you meet specific criteria before the pharmacy will fill the prescription.

Common PA Criteria Across BCBS Plans

While exact language differs by affiliate, the most frequently required criteria include:

• A confirmed diagnosis of insomnia disorder (ICD-10 code G47.00 or G47.09)
• Documentation that the insomnia is not primarily caused by an untreated medical or psychiatric condition
• Age 18 or older
• Trial and failure of (or documented contraindication to) at least one generic sleep medication
• Prescriber is a physician, nurse practitioner, or physician assistant

How Long PA Takes

BCBS affiliates generally process standard PA requests within 48 to 72 hours. Urgent requests (when a delay could seriously harm the patient) must be decided within 24 hours under most state regulations. Your prescriber's office handles the submission. If you have been waiting more than three business days, call both your prescriber's office and the BCBS PA department to check status.

PA Approval Duration

Initial approvals typically last 6 to 12 months. Renewal requires updated documentation that the medication remains effective and that no new contraindications have emerged. Some plans auto-renew if pharmacy claims show continuous fills.

Step Therapy: What BCBS May Require First

Step therapy (sometimes called "fail first") means BCBS requires you to try one or more lower-cost medications before approving Dayvigo. This is one of the most common barriers patients face.

Typical Step Therapy Sequence

Most BCBS step therapy protocols for Dayvigo require documented trial and failure of at least one of the following:

1. A generic Z-drug (zolpidem, zaleplon, or eszopiclone)
2. Trazodone (off-label for insomnia)
3. Suvorexant (Belsomra), the older DORA-class medication

"Failure" can mean the drug was ineffective at adequate dose and duration (typically 2 to 4 weeks), caused intolerable side effects, or is contraindicated based on your medical history. Your prescriber documents the failure in the PA request.

Bypassing Step Therapy

If a generic sleep aid is contraindicated for you (for example, a history of complex sleep behaviors on Z-drugs, or a documented allergy), your prescriber can request a step therapy exception. The American Academy of Sleep Medicine (AASM) clinical practice guidelines note that DORAs like lemborexant are recommended as first-line pharmacotherapy for chronic insomnia in adults, alongside Z-drugs and low-dose doxepin 3. Citing these guidelines in the exception request strengthens the case.

Clinical Evidence Supporting Dayvigo

Understanding the clinical data behind lemborexant helps build a stronger PA or appeal case if BCBS initially denies coverage.

SUNRISE-1 Trial Results

The SUNRISE-1 trial (N=1,006), published in JAMA Network Open in 2019, randomized older adults aged 55 and above with insomnia to lemborexant 5 mg, lemborexant 10 mg, zolpidem extended-release 6.25 mg, or placebo for one month 1. Lemborexant 10 mg reduced latency to persistent sleep by 10.5 minutes more than placebo (P<0.001) and showed statistically significant improvements in wake-after-sleep-onset compared to both placebo and zolpidem ER. The 5 mg dose also outperformed placebo on sleep maintenance endpoints.

SUNRISE-2 Long-Term Data

SUNRISE-2 (N=949) evaluated lemborexant 5 mg and 10 mg against placebo over 12 months in adults aged 18 and above 4. Both doses significantly improved subjective sleep-onset latency and wake-after-sleep-onset through month 12, with no evidence of rebound insomnia upon discontinuation. The most common adverse events were somnolence (reported in approximately 10% of patients on 10 mg), headache, and fatigue.

Safety Profile Relevant to Coverage Decisions

Lemborexant carries a lower risk of next-day impairment compared to some Z-drugs, which is clinically relevant for older adults and patients operating vehicles or machinery. The FDA label notes that the 5 mg starting dose does not require dose adjustment based on age alone 2. This favorable safety profile in the elderly population can be a useful point in PA documentation, especially when the prescriber is arguing against mandatory use of zolpidem in a patient over 65.

How to Appeal a BCBS Denial of Dayvigo

If BCBS denies your prior authorization or step therapy exception, you have the right to appeal. The process follows a predictable structure.

Internal Appeal (First Level)

File a written appeal within 180 days of the denial (or the shorter window stated in your denial letter). Include:

• The denial letter and reference number
• A letter from your prescriber explaining why Dayvigo is medically necessary
• Clinical trial citations (SUNRISE-1, SUNRISE-2) showing efficacy and safety
• Documentation of failed or contraindicated alternatives
• Any relevant AASM guideline references

BCBS must respond to a standard internal appeal within 30 days for non-urgent requests. Urgent appeals require a response within 72 hours.

External Review (Second Level)

If the internal appeal is denied, you can request an independent external review. Under the Affordable Care Act, all non-grandfathered health plans must offer external review by an independent review organization (IRO). The IRO decision is binding on the insurer. File the external review request within 4 months of the internal appeal denial.

State Insurance Department Complaints

If you believe BCBS is not following its own stated coverage policy or is violating state insurance regulations, you can file a complaint with your state department of insurance. This does not replace the appeal process but can accelerate resolution and flag systemic issues.

Using the Eisai Savings Card with BCBS

Eisai, the manufacturer of Dayvigo, offers a copay savings card for commercially insured patients. The card can reduce your out-of-pocket cost to as low as $0 to $30 per month, depending on the terms of the active program.

Eligibility Rules

The savings card is available to patients with commercial insurance (including BCBS commercial plans). It is not available to patients on Medicare, Medicaid, TRICARE, or any other government-funded program. There is typically an annual maximum benefit (often $3,600 to $4,800 per year), after which you pay the full copay.

How to Stack the Card with BCBS

Present the savings card as a secondary payer at the pharmacy. Your BCBS plan processes first, determining your copay or coinsurance. The savings card then covers part or all of that remaining amount. Some BCBS plans with copay accumulator programs will not count the savings card amount toward your deductible or out-of-pocket maximum. Ask your BCBS plan specifically whether they use a copay accumulator or copay maximizer program, because this affects your total annual spend.

Dayvigo Is Not Covered for Weight Loss

BCBS does not cover Dayvigo for weight loss. Period. Lemborexant is FDA-approved exclusively for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance 2. It has no approved weight-loss indication, no clinical trial data supporting weight reduction, and no off-label prescribing pattern for obesity.

If your BCBS plan denied Dayvigo coverage and the denial letter mentions weight loss, confirm with your prescriber that the diagnosis code submitted was for insomnia (G47.00 or G47.09), not an obesity-related code. Incorrect coding is a common and fixable cause of denials.

Alternatives If BCBS Denies or Excludes Dayvigo

If your BCBS plan does not cover Dayvigo and appeals fail, several alternatives exist.

Other Covered Insomnia Medications

• Suvorexant (Belsomra): Another DORA, sometimes on a lower tier. BCBS may prefer it due to longer market history.
• Generic zolpidem: Tier 1 on virtually all BCBS plans. Effective but carries higher risk of complex sleep behaviors and next-day impairment, especially in women and older adults 5.
• Generic eszopiclone: Tier 1 or 2. Similar efficacy profile to zolpidem with some evidence of sustained benefit over 6 months.
• Trazodone: Generic, very inexpensive. Widely prescribed off-label for insomnia though clinical trial evidence for this indication is limited.
• Low-dose doxepin (Silenor): FDA-approved for insomnia maintenance. Generic available. May be on Tier 1 or 2.

Cash-Pay Option

At approximately $85 per month through discount programs, paying cash for Dayvigo may be cheaper than your insured copay on a high-tier plan, especially if you have not met your deductible. Compare the cash price at multiple pharmacies using a discount card before filling through insurance.

Patient Assistance Programs

Eisai offers a patient assistance program (PAP) for uninsured or underinsured patients who meet income eligibility criteria (typically at or below 400% of the federal poverty level). Contact Eisai's patient support line or visit their website for the current application.